New real-world data from the ongoing BICSTaR study demonstrated the continuing benefits of treatment with Gilead’s HIV drug Biktarvy and quality-of-life issues faced by patients who have been treated with the medicine for one year.

George Medicines announced the initiation of two Phase III trials investigating the late-stage drug development company’s proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.

Bausch Health Companies and Ortho Dermatologics announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating the investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical to treat acne vulgaris in patients 9 years of age and older.


Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis (NASH).

The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly’s Trijardy XR for lowering blood sugar in adults with type 2 diabetes.

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s combination therapy to treat smoker’s lung.

Array BioPharma announced positive results from the Phase III BEACON CRC trial evaluating a triple combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovia (binimetinib), and the anti-EGFR antibody Erbitux (cetuximab) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer after one or two lines of therapy.

Independent experts of an FDA advisory panel voted in favor of the not-for-profit TB Alliance’s treatment for drug resistant tuberculosis, as a part of a three-drug combination regimen.

New interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that Biogen’s investigational treatment diroximel fumarate was generally well tolerated in people with relapsing MS.